Sale!

LL-37 (Cap-18)

£35.99 £26.99

5 mg Vial

LL-37 is widely recognised for its antimicrobial properties.

400 in stock

SKU LL-37 (Cap-18) Categories , ,

Description

LL-37 (Cap-18) 5mg Peptide Vial

Recent studies by our group have shown that peptide LL-37 is an antiseptic agent that can be used to treat fungal infections and bacterial infections. It has proved to be useful against bacterial skin infections, particularly in cases where the disease is resistant to most anti-fungal agents. In addition, it has also shown promise in fighting against bacterial skin infections due to fungal causes, such as candida albicans. Recently, researchers have been studying the peptide LL-37’s benefits for cathelicidic dermatitis and how this substance can benefit people with this chronic skin disorder.

LL-37 can be used to treat cathelicidic dermatitis as this substance has proved effective in reducing the inflammation caused by this condition. This Peptide works by inhibiting the production of proinflammatory cytokines, which is one of the main causes of inflammation that can be attributed to cathelicidic dermatitis. As a result, it helps to eliminate the yeast and bacteria that cause cathelicidic skin disorder, thus relieving the symptoms associated with the condition.

LL-37 Specifications

Molecular Formula: C205H340N60O53
Sequence: H-Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser-OH
Molecular Weight: 4493 g/mol
Physical Appearance: White Lyophilised Solid
Form: Sterile Filtered White Lyophilized
Solubility: Water Soluble

LL-37 Storage: -20˚C

Disclaimer:

All products listed on this website and provided through Pharma Labs Global are intended for medical research purposes only. Pharma Lab Global does not encourage or promote the use of any of these products in a personal capacity (i.e. human consumption), nor are the products intended to be used as a drug, stimulant or for use in any food products.

You may also like…